Login to Your Account

Advaxis Stock Sale Draws $23M; Phase II Cancer Bids Under Way

By Randy Osborne
Staff Writer

Friday, October 18, 2013

Cancer immunotherapy gained another stamp of approval with the $23 million in gross proceeds raised by Advaxis Inc., which sold about 5.7 million shares plus warrants to buy about 2.8 million more, at a price of $4 per share and $0.01 per warrant.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription